Health&Life Co

Health&Life Co Equity Ratio

The Equity Ratio of Health&Life Co (1781.TWO) as of Nov 6, 2026 is 44.33 %. In the previous year, Equity Ratio was 48.09 % — a change of -7.82% (lower).

Equity Ratio

44.33 %

YoY

-7.82%

Last updated:

Equity Ratio of Health&Life Co is 2025 44.33 % . Equity Ratio of Health&Life Co was 2024 48.09 % . It decreases by -7.82% lower compared to the previous year.

The Health&Life Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
58.80 TWD
Jan 1, 2019
46.64 TWD
Jan 1, 2020
43.69 TWD
Jan 1, 2021
48.71 TWD
Jan 1, 2022
46.59 TWD
Jan 1, 2023
47.18 TWD
Jan 1, 2024
48.09 TWD
Jan 1, 2025
44.33 TWD
The Health&Life Co Equity Ratio history
YEAREquity RatioYoY
44.33 %-7.82%
48.09 %+1.93%
47.18 %+1.28%
46.59 %-4.36%
48.71 %+11.49%
43.69 %-6.31%
46.64 %-20.69%
58.80 %-14.19%
68.52 %-4.24%
71.56 %-9.65%
79.20 %+7.25%
73.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Equity Ratio of Health&Life Co is 44.33 % in 2025.

Equity Ratio of Health&Life Co changed from 48.09 % to 44.33 %, representing a -7.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Health&Life Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Health&Life Co

All Key Metrics — Health&Life Co